Patent ID: 11873349
Assignee: SYNTHEKINE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An IL27 receptor (IL27R) binding protein that specifically binds to IL27Rα subunit (IL27Rα) and glycoprotein 130 subunit (gp130),
wherein the binding protein causes the multimerization of IL27Rα and gp130 when bound to IL27Rα and gp130, and
wherein the binding protein comprises a single-domain antibody (sdAb) that specifically binds to IL27Rα (an anti-IL27Rα sdAb) and a sdAb that specifically binds to gp130 (an anti-gp130 sdAb) and wherein the anti-IL27Rα sdAb is an anti-IL27Rα VHH antibody and the anti-gp130 sdAb is an anti-gp130 VHH antibody and
wherein the anti-gp130 VHH antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of:
SEQ ID NO: 193, SEQ ID NO: 199, SEQ ID NO: 205, respectively;
SEQ ID NO: 194, SEQ ID NO: 200, SEQ ID NO: 206, respectively;
SEQ ID NO: 195, SEQ ID NO: 201, SEQ ID NO: 207, respectively;
SEQ ID NO: 196, SEQ ID NO: 202, SEQ ID NO: 208, respectively;
SEQ ID NO: 197, SEQ ID NO: 203, SEQ ID NO: 209, respectively; and
SEQ ID NO: 198, SEQ ID NO: 204, SEQ ID NO: 210, respectively; and
the anti-IL27Rα VHH antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of
SEQ ID NO: 211, SEQ ID NO: 218, SEQ ID NO: 225, respectively;
SEQ ID NO: 212, SEQ ID NO: 219, SEQ ID NO: 226, respectively;
SEQ ID NO: 213, SEQ ID NO: 220, SEQ ID NO: 227, respectively;
SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively;
SEQ ID NO: 215, SEQ ID NO: 222, SEQ ID NO: 229, respectively;
SEQ ID NO: 216, SEQ ID NO: 223, SEQ ID NO: 230, respectively; and
SEQ ID NO: 217, SEQ ID NO: 224, SEQ ID NO: 231, respectively.